19 results about "Colony-stimulating factor" patented technology

The application discloses a use of Ejiao Qianggu oral liquid in regulating immunity, and particularly relates to an improving effect of the Ejiao Qianggu oral liquid on an immune system, which is realized by the following aspects. On one hand, the Ejiao Qianggu oral liquid promotes proliferation and transformation (mainly early T lymphocytes and part of B lymphocytes) and active functions of spleen lymphocytes; on the other hand, the Ejiao Qianggu oral liquid improves phagocytosis of macrophages. The Ejiao Qianggu oral liquid has the following characteristics: firstly, the Ejiao Qianggu oral liquid acts on early lymphocyte maturation, and has no significant effect on proliferation of peripheral blood lymphocytes; secondly, the Ejiao Qianggu oral liquid can significantly act on immune target organs, thymus and spleen tissues, and does not excessively stimulate the spleen, unlike positive drugs such as colony stimulating factor which can cause significant edema of the spleen; and thirdly, the Ejiao Qianggu oral liquid has a significant recovery effect on body weight, white blood cells, lymphocytes, red blood cells and hemoglobin in blood of patients with low immunity.

The application provides a hyaluronic acid artificial lymph node sustained-release nano DNA vaccine for enhancing cancer prevention effect and a preparation method thereof, and the preparation raw materials comprise a plasmid, 4-(bromomethyl)phenyl boronic acid modified linear polyethylene imine, a cell colony stimulating factor, a sulfhydryl modified hyaluronic acid and a four-arm-maleimide grafted polyethylene glycol. The nano DNA vaccine can recruit a large number of immune cells to form a hyaluronic acid artificial lymph node after subcutaneous administration, and inhibit the generation of tumors by continuously outputting antigen presenting cells and antigen specific T cells. In addition, the hyaluronic acid artificial lymph node can also release the nano DNA vaccine, prolong the vaccine stimulation time, improve the problem of weak immunogenicity of the existing DNA vaccine, and also solve the problem of biocompatibility. The nano DNA vaccine has the advantages of easy preparation, easy storage, low price and the like.

The present disclosure provides methods of treating chronic graft versus host disease (cGVHD) using antibodies that bind to colony stimulating factor 1 receptor (CSF-1R).

The invention relates to the field of neurology, neurobiology, and neurological disorders. The invention relates to a pharmaceutical combination comprising a colony-stimulating factor 1 receptor (CSFR1R) inhibitor and a bone marrow cell population for use in the treatment of central nervous system (CNS) diseases. The invention further relates to an ex vivo method for depleting dysfunctional and / or mutant microglia and / or CNS-associated macrophages (CAM), the method comprising providing a population of cells comprising myeloid cells and treating said cells with an CSF1R inhibitor of central nervous system (CNS)-associated myeloid cells, thereby depleting dysfunctional and / or mutant microglia. The invention relates to a cell population according to the ex vivo method. The invention further relates to a pharmaceutical composition comprising the CSF1R inhibitor according to the present invention for use in the treatment or prevention of a medical condition induced by dysfunction of immune cells in a central nervous system (CNS), additionally comprising a pharmaceutically acceptable carrier.

The invention provides application of a neutralizing antibody of a targeted macrophage to preparation of a medicine for treating atopic dermatitis (AD), relates to the technical field of biomedicine, and is characterized in that the neutralizing antibody of the targeted macrophage is provided to deplete the macrophage so as to treat the AD. The method is characterized in that a neutralizing antibody capable of specifically recognizing and combining a key target spot-colony stimulating factor 1 receptor (CSF1R) on the surface of the macrophage is applied to block a CSF1 / CSF1R signal channel, so that the macrophage for driving the AD pathological process is eliminated. According to the application, the atopic dermatitis (AD) is treated by applying the neutralizing antibody targeting the key target spot of the macrophage, and remarkable and multi-aspect beneficial technical effects are generated. The effects are verified in an AD mouse model induced by MC903 and are specifically reflected in relieving of disease core symptoms, intervention of key pathological links and improvement of overall health conditions, and a foundation is laid for clinical treatment of atopic dermatitis.

Colony Stimulating Factor, CSF, refers to a family of four glycoproteins that control and coordinate cell production by widely scattered deposits of marrow cells. GM-CSF is a hematologic growth factor that regulates the production, migration, proliferation, differentiation and function of hematopoietic cells. The present disclosure relates generally to compositions and methods related to long acting and granulocyte-macrophage colony-stimulating factor (GM-CSF) with improved pharmacokinetics.

The present disclosure provides, among other things, anti-CSF1R single-domain antibodies (sdAbs) with high affinity to CSF1R (e.g., KD of pM to low nM) and therapeutic uses of such sdAbs in effectively treating CSF1R mediated diseases, such as age-related macular degeneration (AMD). In some embodiments, an anti-CSF1R sdAb is fused to an Fc region.

The invention relates to a composition and application of the composition in preparation of drugs for treating Alzheimer's disease, the composition comprises hematopoietic stem cells modified by an adenine base editing system and a colony stimulating factor 1 receptor inhibitor, the use method of the medicine for treating the Alzheimer disease comprises the following steps: S1, using the colony stimulating factor 1 receptor inhibitor to deplete microglial cells in the brain; s2, performing marrow removal pretreatment; s3, transplanting the hematopoietic stem cells modified by an adenine base editing system, wherein the adenine base editing system is used for correcting R47H site mutation of the TREM2 gene in the hematopoietic stem cells; experiments prove that when the base editing system and the CSF1 inhibitor are combined for use, microglial cells in the brain can be replaced, A beta load in the brain can be reduced, neuroinflammation can be relieved, cognitive impairment can be improved, the effect is remarkably superior to that of a single therapy, and an unprecedented comprehensive treatment scheme is provided for solving systematic immunodeficiency of the Alzheimer disease.

The present invention is directed to a method for producing granulocytes and / or precursors thereof for therapeutic use, the method comprising culturing progenitor cells in a cell culture medium comprising: (a) an inhibitor of p38 MAP kinase; (b) granulocyte macrophage-colony stimulating factor (GM-CSF); and (c) interleukin-3 (IL-3). Also provided are a granulocyte and / or precursor thereof, population of cells, composition, kit, and therapeutic uses thereof.

The present invention relates to a monoclonal antibody, or fragment thereof, which binds to CSF-1R (Colony stimulating factor 1 receptor), in particular to human CSF-1R. The present invention further relates to the in vitro use of the monoclonal antibody, or fragment thereof, of the present invention for the detection of CSF-1R in a sample. Further encompassed by the present invention is a complex comprising the monoclonal antibody, or fragment thereof, of the present invention and CSF-1R such as the human CSF-1R polypeptide.

The present disclosure provides methods and compositions for microglia replacement therapy in a subject in need thereof. In some cases, the method involves administering myeloid cells to the central nervous system of a subject. In some cases, the myeloid cells are derived from embryonic or extraembryonic tissue. In some cases, the myeloid cells are genetically modified. The genetic modification may include a colony stimulating factor 1 receptor (CSF1R) variant that is resistant to a CSF1R inhibitor, yet retains sensitivity to its ligand (e.g., CSF1, IL34).

Heterocyclic compounds of formula I shown below and pharmaceutical compositions containing one of such compounds: Also disclosed is a method of treating a condition modulated by the colony-stimulating factor-1 receptor with one of the heterocyclic compounds.

Conjugates of a CSF-1 moiety and one or more water soluble polymers are provided. Typically, the water soluble polymer is a poly(ethylene glycol) or a derivative thereof. Also provided are compositions comprising conjugates, methods of making conjugates, methods of using the conjugates or compositions in therapeutic treatments, methods of administering conjugates or compositions comprising the conjugates to a patient, and kits comprising conjugates.

The present disclosure provides methods and compositions for microglia replacement therapy in a subject in need thereof. In some cases, the method involves administering myeloid cells to the central nervous system of a subject. In some cases, the myeloid cells are derived from embryonic or extraembryonic tissue. In some cases, the myeloid cells are genetically modified. The genetic modification may include a colony stimulating factor 1 receptor (CSF1R) variant that is resistant to a CSF1R inhibitor, yet retains sensitivity to its ligand (e.g., CSF1, IL34).

The present invention relates to an agonist of the colony stimulating factor 1 receptor (CSF1R) for use in the prophylaxis and / or treatment of viral infections in states of immunosuppression in a subject and to pharmaceutical compositions comprising said CSF1R agonist. According to the invention, said subject is in a state of immunosuppression, when in said subject the absolute number of CD14+, CD16+ und HLA-DR+ expressing monocytes is reduced when compared to a healthy control subject. The invention is based on the finding that CSF1R agonist treatment, such as M-CSF treatment, induces an integrated multistep differentiation cascade that culminated in increased NK cell activation protecting HCT recipients from a viral infection. A mechanism of action by which M-CSF-induced myelopoiesis can rapidly reconstitute antiviral activity under immunosuppressed conditions was identified, which provides a general paradigm to boost innate antiviral immune response.

The present disclosure provides antibodies that binds to human colony stimulating factor 1 receptor (CSF-1R) and methods of treating chronic graft-versus-host disease (cGVHD) with the antibodies.

This invention discloses pyrazolopyridine or pyrazolopyrimidine compounds or salts thereof with colony-stimulating factor-1 receptor (CSF1R) inhibitory activity, their medical uses for treating, preventing, and / or diagnosing CSF1R-related diseases, and methods for preparing said compounds or salts thereof. The provided invention includes a compound or salt thereof represented by formula [I], its medical uses, and its preparation method, wherein R... 1 It is hydrogen, etc.; R 21 and R 22 It is hydrogen, or R 21 and R 22 Together with the adjacent heterocyclic ring, it forms a bridging double ring; R 3 It is optionally controlled by one or more R 32 Replaced -L 31 -R 31 Or optionally by one or more R 32 Replacement R 31 L 31 It is -C(=O)- etc.; R 31 It is C 1‑6 Alkyl groups, etc.; R 32 Each is independently a halogen, etc.; and X is a CR. 1 Or N.

The present invention relates to a treatment regime, including an antibody or antigen-binding fragment which is capable of binding specifically to colony stimulating factor-1 receptor (CSF-1R) for use in the treatment of tenosynovial giant cell tumour (TGCT) in a subject, as well as associated uses and methods.

A recombinant nucleic acid molecule is encoded at least by an ORF to lower a cytokine storm during immunotherapy. The recombinant nucleic acid molecule includes at least one first hairpin loop structure, at least one second hairpin loop structure and a first promoter. The first and second hairpin loop structure regulates an amount of Granulocyte monocyte colony stimulating factor (GMCSF) cytokine and Interleukin 6 (IL6) cytokine, respectively. The first hairpin loop structure is formed by at least two first short hairpin RNA sequences and at least one microRNA30 sequence. The second hairpin loop structure is formed by at least two second short hairpin RNA sequences and at least one microRNA30 sequence. The first promoter is disposed upstream of the first and second hairpin loop structure.